Tioptropium as a controller of bronchoconstriction;Tiotropium w kontrolowaniu obturacji oskrzeli

Polski Merkuriusz Lekarski

Volumn 16, Issue SUPPL. 1, 2004, Pages 75-78

  Lubiński, Wojciech ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Chronic obstructive pulmonary disease (COPD); Tiotropium

Indexed keywords

MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; POSTSYNAPTIC RECEPTOR; TIOTROPIUM BROMIDE;

ACETYLCHOLINE RELEASE; AIRWAY DYNAMICS; AMBIGUUS NUCLEUS; BRAIN STEM; BRONCHODILATATION; BRONCHOSPASM; CHOLINERGIC NERVE; DISSOCIATION; DYSPNEA; HEALTH STATUS; HUMAN; LUNG DISEASE; LUNG FUNCTION; MOTONEURON NUCLEUS; MUCOUS CELL; MUSCLE INNERVATION; NEGATIVE FEEDBACK; NERVE FIBER; PARASYMPATHETIC GANGLION; POSTGANGLIONIC NERVE; REVIEW; SMOOTH MUSCLE; SUBMUCOSA; VAGUS NERVE;

BRONCHI; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, MUSCARINIC; SCOPOLAMINE DERIVATIVES;

EID: 17344379601     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Brusasco V. i wsp.: Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax, 2003, 58, 399.
2. Casaburi R. i wsp.: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J., 2002, 19, 217.
3. Dahl R. i wsp.: Comparison of the efficacy and safety of inhaled formoterol and ipratropium bromide in patients with COPD. Am. J. Respir. Crit. Care Med., 2000, 161, 805.
4. Donohue J.F. i wsp.: Tolerance to bronchodilating effects of salmeterol in COPD. Respiratory Medicine, 2003, 97, 1014.
5. Donohue J.F. i wsp.: A 6-Month Placebo - Controled Study Comparing Lung Function and Health Status Changes in COPD Patients treated With Tiotropium or Salmeterol. Chest, 2002, 122, 1, 47.
6. Greefhorst A. i wsp.: Effect of inhaled formoterol and ipratropium bromide on quality of life, "bad days" and exacerbations in patients with COPD. Am. J. Respir. Crit. Care Med., 2000, 161, 807.
7. Hansel T.T., Barnes P.J.: Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs of Today, 2002, 38, 9, 585.
8. Hvizdos K.M., Goa K.L.: Tiotropium bromide. Drug, 2002, 62, 8, 1195.
9. Lubihski W., Targowski T., Płusa T.: Co należy wiedzieċ o przewlekłej obturacyjnej chorobie płuc. Medpress, 2002, ISBN 83-916116-0-4.
10. Lubiṅski W. i wsp.: Analiza sposobu leczenia chorych na POChP. Pol. Merk. Lek., 2003, 15, 90, 547.
11. Miguel Diez Jd.J. i wsp.: Drug treatment of chronic obstructive pulmonary disease on two levels of patient care: degree of compliance with recommended protocols. Arch. Bronconeumol., 2003, 39, 5, 195.
12. Slomiński J.M.: rola układu cholinergicznego i leków cholinolitycznych w terapii chorób bronchoobturacyjnych. Kurier Medyczny, czerwiec 2003, 1.
13. Slomiński J.M. i wsp.: leczenie chorych na przewlekla̧ obturacyjná chorobȩ płuc. Pol. Merk. Lek., 2004, 16, 92, 133.
14. Van Noord J. i wsp.: Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effects of ipratropium. Eur. Respir. J., 2000, 15, 878.
15. Vincken W. i wsp.: Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J., 2002, 19, 209.